ALK-Abelló Nachrichten

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• 
  ALK-Abelló Pharmaceuticals Inc Announces Positive Funding Recommendation from Canada's Drug Agency for neffy® for the Emergency Treatment of Allergic Reactions (Anaphylaxis) (öffnet in neuem Tab)

  01.10.2026

• ALK expands strategic tablet supply partnership with Catalent (öffnet in neuem Tab)

  30.09.2026

• Why ALK-Abelló (CPSE:ALK B) Is Getting Attention Today (öffnet in neuem Tab)

  23.09.2026

• 
  ALK appoints Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy (öffnet in neuem Tab)

  21.09.2026

• ALK to present at the Morgan Stanley Global Healthcare Conference in New York (öffnet in neuem Tab)

  11.09.2026

• Alk-Abello AS (AKBLF) (Q2 2026) Earnings Call Highlights: Strong Tablet Sales and Raised ... (öffnet in neuem Tab)

  20.08.2026

• ALK appoints Jacob Glenting as head of Global R&D (öffnet in neuem Tab)

  20.08.2026

• Six-month interim report (Q2) 2026 (unaudited) (öffnet in neuem Tab)

  20.08.2026

• ALK’s tree pollen and house dust mite tablets now recommended by NICE for paediatric treatment in the UK health system (öffnet in neuem Tab)

  14.08.2026

• Invitation to the presentation of ALK’s first six months (Q2) 2026 results on Thursday, 20 August 2026 (öffnet in neuem Tab)

  13.08.2026

• Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada (öffnet in neuem Tab)

  05.08.2026

• Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight (öffnet in neuem Tab)

  27.07.2026

• Is It Too Late To Consider ALK-Abelló (CPSE:ALK B) After Strong Multi‑Year Gains? (öffnet in neuem Tab)

  05.06.2026

• ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026 (öffnet in neuem Tab)

  04.06.2026

• ALK to present at the Jefferies Global Healthcare Conference in New York (öffnet in neuem Tab)

  29.05.2026

• Three-month interim report (Q1) 2026 (unaudited) (öffnet in neuem Tab)

  04.05.2026

• ALK upgrades its full-year outlook (öffnet in neuem Tab)

  04.05.2026

• Assessing ALK Abelló (CPSE:ALK B) Valuation After Strong Recent Share Price Momentum (öffnet in neuem Tab)

  02.05.2026

• Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026 (öffnet in neuem Tab)

  28.04.2026

• Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff (öffnet in neuem Tab)

  08.04.2026